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Doxazosin, an a1-adrenergic receptor
inhibitor, is commonly administered to
patients with type 2 diabetes, hypertension
and nephropathy. The impact of 3 months’
doxazosin therapy on the prevalence of
activated and regulatory T lymphocytes
was analysed in this pilot study of men
with type 2 diabetes (n = 10) who received
doxazosin 4 mg/day in addition to their
ongoing therapy. The prevalence of CD4+,
CD8+, CD25+ and CD69+ cells at baseline
and after 3 months of add-on therapy was
determined. The prevalence of regulatory
T-cells was detected by two different
approaches: forkhead box P3 (FoxP3)
positivity; and the number of
CD4+CD25+high cells. During 3 months of
doxazosin therapy, patients’ blood
pressure, blood glucose control and lipid
profiles all significantly improved.
Simultaneously, the prevalence of activated
T-cells (CD4+CD69+ and CD8+CD69+ cells)
decreased, whereas that of regulatory T-
cells increased. These results indicate an
immunomodulatory action of doxazosin in
type 2 diabetic patients.
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Introduction
Current guidelines recommend the use of
renin–angiotensin–aldosterone system
(RAAS) inhibitors in diabetic patients with
microalbuminuria.1 These agents prevent
cardiovascular and renal morbidity2 and all-
cause mortality.3 The protection provided is
proportional to the improvement of
proteinuria.4 Some patients do not, however,
respond sufficiently. This situation requires
the introduction of another antihypertensive
agent.5 Doxazosin, a selective α1-adrenergic
receptor blocker, is used widely for this
purpose as it improves morning surge
hypertension, decreases albuminuria in
patients with type 2 diabetes,6 and results in
improvements of left ventricular mass index,
plasminogen-activator inibitor-1 levels, lipid
profiles, blood glucose control and
endothelial dependent vasodilation.7,8
Studies have also reported
immunomodulatory actions of doxazosin.
For example, in hypertensive patients, high
sensitivity C-reactive protein (hsCRP) has
been shown to decrease after 4 months of
doxazosin therapy.9 Doxazosin has also
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been shown to increase intracellular
adhesion molecule-1 and CD40 expression,
and interleukin-18 production by human
peripheral monocytes, suggesting the
modulation of innate immunity.10
There are no data on the impact of
doxazosin on adaptive immunity. Epstein–
Barr virus has been shown to transform B
lymphocyte surface expression of α1- and α2-
receptors,11,12 providing a theoretical
opportunity to study the immuno-
modulatory action of α1-adrenergic receptor
blockers. Prazosin, another member of this
pharmaceutical class, has been shown to
delay the progression of autoimmune
encephalitis (a T-cell mediated disorder) in
animals.13
The present pilot study was designed to
evaluate the effect of doxazosin on the
prevalence of activated CD4+ and CD8+ T
lymphocytes and regulatory (CD4+ forkhead
box P3 positive [FoxP3+]) T-cells (Treg cells) in
patients with type 2 diabetes.
Patients and methods
PATIENTS
Male patients with type 2 diabetes who
regularly attended the Diabetes Outpatient
Clinic of Miskolc Healthcare Centre, Miskolc,
Hungary, were enrolled into this pilot study
between March and May 2007. Inclusion
criteria were persisting microalbuminuria
(albumin excretion ≥ 30 mg/day) and
morning surge hypertension (blood pressure
> 130/85 mmHg). Patients with infection,
malignancies or known allergies were
excluded.
Each participant gave written informed
consent. The study was carried out in
accordance with the ethical standards of the
Declaration of Helsinki (revised 1983) and
the protocol was approved by the BAZ
County Regional Ethical Council, Miskolc,
Hungary.
STUDY DESIGN AND ASSESSMENTS
Patients’ systolic and diastolic blood pressures
and clinical chemistry were obtained at visit
1, before administration of doxazosin 4 mg
once a day (Cardura® XL; Pfizer, New York,
NY, USA), which uses a gastrointestinal
therapeutic system (GITS) to provide a
controlled rate of drug delivery into the
gastrointestinal lumen. The dose regimens of
any other drugs at baseline were to remain
unchanged during the study. After 3 months
of treatment, patients’ blood pressure and
clinical chemistry were reassessed (visit 2).
On visits 1 and 2, 5 ml of blood was taken
into commercially available heparin-
containing tubes (BD Vacutainer®; Becton
Dickinson & Co., Plymouth, UK). Peripheral
blood mononuclear cells were separated
from whole blood using a Ficoll–Paque™
Plus gradient (GE Healthcare Bio-Sciences,
Uppsala, Sweden) within 6 h after sampling
as previously described14 and stored at –80 °C
until measurements were carried out (within
1 month). Patients’ systolic and diastolic
blood pressures and clinical chemistry,
including glycated haemoglobin (HbA1c),
total cholesterol, low-density lipoprotein-
cholesterol (LDL-C), high-density
lipoprotein-cholesterol (HDL-C) and
triglyceride levels, microalbuminuria, high
sensitivity C-reactive protein (hsCRP) plasma
concentration, and estimated glomerular
filtration rate (Cockcroft–Gault method),
were assessed at both visits. At visits 1 and 2,
measurement of intracellular FoxP3 and
detection of CD4, CD8, CD25 and CD69 cell
surface markers were performed as described
previously.14 Blood pressure was measured at
visits 1 and 2 by ambulatory blood pressure
monitoring. For measurement of
microalbuminuria, 200 ml of 24-h urine was
used in an immunoassay method (Tina-
quant albumin immunoturbidimetric assay
(Roche Diagnostics, Basel, Switzerland).
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STATISTICAL ANALYSIS
The prevalence of different cell types before
and after 3 months of doxazosin therapy
was compared using the paired non-
parametric Wilcoxon test. A P-value < 0.05
was considered to be statistically significant.
Statistical analysis were carried out using the
‘R’ software package (The ‘R’ Foundation for
Statistical Computing, Vienna, Austria;
http://www.r-project.org).
Results
A total of 10 men with type 2 diabetes were
enrolled into this study. Their baseline
clinical characteristics and baseline
therapies are shown in Table 1.
Table 2 summarizes the impact of 3
months of therapy with doxazosin 4 mg once
a day on patients’ cardiovascular risk profile
and the various laboratory tests. At the end
of the 3 months of therapy, morning surge
hypertension, levels of HbA1c, total
cholesterol and LDL-C, and micro-
albuminuria were significantly decreased
(P < 0.05) compared with baseline levels.
There were no significant changes in HDL-C,
triglycerides, hsCRP and estimated
glomerular filtration rate compared with
baseline. There were marked changes in
prevalence of the different immune cell types
investigated, including statistically
significant increases in CD4+FoxP3+/CD4+
(P = 0.009) and CD4+CD25+high/CD4+ (P =
0.001) cell ratios, and statistically significant
decreases in CD4+CD69+/CD4+ (P = 0.003)
and CD8+CD69+/CD8+ (P = 0.022) cell ratios.
TABLE 1:
Clinical characteristics and baseline therapy of 10 male type 2 diabetes patients who
received 3 months of doxazosin (4 mg once a day) add-on therapy
Age (years), median (range) 53 (46 – 63)
Time of diagnosis of diabetes prior to the study (years), median (range) 7.6 (2 – 13)
Time of diagnosis of hypertension prior to the study (years), median (range) 10.7 (1 – 25)
Body mass index (kg/m2), median (range) 30.9 (25.5 – 41.9)
Diabetes-related complications, n
Microalbuminuria 10
Retinopathy (mild stage) 3
Neuropathy 3
Ischaemic heart disease (mild stage) 6
Baseline therapy, n
Metformin (2 × 850 mg/day / 3 × 850 mg/day) 10 (4/6)
Acarbose (3 × 50 mg/day / 2 × 100 mg/day) 4 (3/1)
ACE inhibitor (ramipril/lisinopril/fosinopri/enalapril) 8 (4/1/1/2)
ARB (irbesartan/telmisartan) 2 (1/1)
Conventional insulin regimen 2
Analogue insulin regimen 1
Calcium channel blocker (amlodipin/felodipin) 5 (4/1)
β-Blocking agent (bisoprolol/carvedilol) 4 (3/1)
Acetylsalicylic acid 6
Diuretics: thiazides (hydrochlorothiazide) 3
Diuretics: furosemide 1
Statins: simvastatin/fluvastatin 2 (1/1)
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
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Discussion
The main finding of this pilot study was that
3 months of therapy with doxazosin 4 mg
once a day was associated with an
improvement in cardiovascular risk factors
and changes in adaptive immunity (a
decrease in the prevalence of activated
lymphocytes and an increase in the
prevalence of regulatory CD4+ lymphocytes)
in patients with type 2 diabetes.
The beneficial effects of doxazosin used as
a second- or third-line agent on
cardiovascular risk factors have been
demonstrated in different hypertensive
patient populations (including patients with
diabetes, obesity and hypercholesterol-
aemia) in a large meta-analysis.15 Indeed,
even in the small patient population used in
the present study a significant decrease in
morning surge and daytime hypertension
was observed, as well as an improvement in
proteinuria, lipid profile and blood glucose
control. These findings are in line with
previous observations.6,7
The immunomodulatory action of
doxazosin is a novel observation. The
pharmaceutical target of doxazosin, α1-
adrenergic receptors, are expressed by not
only the vascular wall, but also by a number
of other tissues and cells, including
Before doxazosin After 3 months of Statistical
Blood pressure and laboratory tests (visit 1) doxazosin (visit 2) significance
Arterial blood pressure (mmHg)a
SBP between 08:00 h and 21:00 h 134 (111 – 192) 128 (100 – 157) P = 0.022
DBP between 08:00 h and 21:00 h 82 (63 – 107) 74 (60 – 93) P = 0.013
SBP between 04:00 h and 07:00 h 159 (138 – 206) 142 (131 – 190) P = 0.001
DBP between 04:00 h and 07:00 h 97 (82 – 129) 80 (71 – 101) P = 0.002
HbA1c (%) 7.65 (5.2 – 9.0) 6.70 (4.9 – 8.9) P = 0.013
Total cholesterol (mmol/l) 5.35 (3.60 – 7.57) 5.13 (4.11 – 6.39) P = 0.015
LDL cholesterol (mmol/l) 3.58 (2.45 – 5.63) 3.46 (2.30 – 4.42) P = 0.007
HDL cholesterol (mmol/l) 1.19 (0.87 – 1.59) 1.29 (0.69 – 1.57) NS
Triglyceride (mmol/l) 2.6 (0.86 – 3.75) 1.91 (0.80 – 4.55) NS
Estimated GFR, Cockcroft–Gault
method (ml/min) 92.0 (43.5 – 114.6) 99.9 (68.2 – 131.7) NS
Microalbuminuria (mg/day) 141.5 (53 – 1125) 9.5 (3 – 548) P = 0.013
hsCRP (mg/l) 3.15 (1.02 – 10.70) 2.10 (1.1 – 17.0) NS
Activated T-cell prevalence
CD4+CD69+/CD4+ 2.32 (1.28 – 4.01) 0.61 (0.40 – 2.50) P = 0.003
CD8+CD69+/CD8+ 2.91 (1.52 – 5.10) 1.49 (0.30 – 4.13) P = 0.022
Regulatory T cell prevalence
CD4+CD25+high/CD4+ 4.58 (2.82 – 9.66) 8.21 (5.66 – 16.48) P = 0.001
CD4+FoxP3+/CD4+ 1.92 (0.04 – 4.73) 4.59 (1.07 – 9.09) P = 0.009
Data are shown as median (range).
aArterial blood pressure measured by 24-h ambulatory blood pressure monitoring.
SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; GFR, glomerular filtration rate; hsCRP, high sensitivity C-reactive
protein; FoxP3, forkhead box P3; NS, not statistically significant (P > 0.05).
TABLE 2:
Blood pressure, laboratory data, microalbuminuria and prevalence of investigated cell
types in 10 male patients with type 2 diabetes measured before and after 3 months of
doxazosin (4 mg once a day) add-on therapy
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lymphocytes. It has been suggested that α1-
receptors play a role in the development of T
lymphocytes in the thymus.16 In vivo,
catecholamines inhibit the production of
pro-inflammatory cytokines and contribute
to the skewing of the immune system
towards Th2 cell development. While
lymphocyte function is predominantly
modulated by α2-adrenergic receptors,
17 it is
thought that α1-adrenergic receptors may
also play at least a partial role.18
The present study indicates that the
prevalence of Treg cells, a lymphocyte
subtype responsible for controlling the
adaptive immune response, is increased after
3 months of doxazosin therapy in patients
with type 2 diabetes. This increase in
prevalence of Treg cells may be of major
clinical importance. While the significance of
low numbers of Treg cells in the progression
and complications of atherosclerosis is
supported by both animal and human
data,19 – 21 no therapeutic approach exists to
promote an increase in this particular cell
type. The present study indicates that the
modulation of adrenergic receptors in type 2
diabetic patients may be a way to produce
higher numbers of Treg cells. The mechanism
behind this phenomenon is, however,
currently unclear; improved blood glucose
control, immunomodulatory action on
innate immune cells and/or even a direct
effect on α1-adrenergic receptors may
potentially contribute to an increase in the
numbers of Treg cells.
As well as an increase in the number of
Treg cells, the number of activated CD4+ and
CD8+ T-cells decreased during doxazosin
therapy in the present study. This may be
characteristic of a systemic anti-
inflammatory action, although this was not
reflected by the stable levels of hsCRP
observed during the course of the study,
which may have been due to a low baseline
level. The limited data from the present
study do not allow us to determine
definitively whether this lower activation is
due to an increased number of Treg cells, the
result of the inhibition of α1-adrenergic
receptors, or an improved metabolic state.
In conclusion, the present study indicates
an immunomodulatory action of α1-
adrenergic receptor inhibitor therapy in type
2 diabetic patients. Further studies are
required to establish whether this effect
contributes to protection against
cardiovascular complications in this high-
risk population.
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